* staff members who do not provide direct care to residents. * residents with active sars-cov-2 infection present, or with symptoms compatible with covid19 confirmed by pcr test. * staff members with present or past sars-cov-2 infection, or with pcr-confirmed symptoms consistent with covid19. * history of qt interval prolongation or arrhythmias of any etiology. * presence of retinopathy of any etiology, changes in acuity or visual field. * severe hearing loss (requires the use of hearing aids). * structural heart disease. * history of non-structural heart failure, ischemic heart disease, scasest, or scacest * chronic liver disease. * alcoholism. * epilepsy. * for the participating professionals, pregnancy or suspected pregnancy (if they are planning pregnancy, or in fertilizer treatment, they must abandon the study). * subjects with known hdq hypersensitivity. * subjects diagnosed with g6pdh deficiency. * taking other medicines that prolong qt: domperidone, ondansetron, cilostazol, antiarrhythmics (procainamide, amiodarone, flecainide, sotalol), macrolides (azithromycin, clarithromycin, erythromycin), quinolones (ciprofloxacin,), moxofloxacin,) neuroleptics (haloperidol, chlorpromazine, pimozide), antidepressants (citalopram, escitalopram), sulpiride, anticholinesterase drugs (donepezil) * denial to participate in the study

* staff members who do not provide direct care to residents. * residents with active sars-cov-2 infection present, or with symptoms compatible with covid19 confirmed by pcr test. * staff members with present or past sars-cov-2 infection, or with pcr-confirmed symptoms consistent with covid19. * history of qt interval prolongation or arrhythmias of any etiology. * presence of retinopathy of any etiology, changes in acuity or visual field. * severe hearing loss (requires the use of hearing aids). * structural heart disease. * history of non-structural heart failure, ischemic heart disease, scasest, or scacest * chronic liver disease. * alcoholism. * epilepsy. * for the participating professionals, pregnancy or suspected pregnancy (if they are planning pregnancy, or in fertilizer treatment, they must abandon the study). * subjects with known hdq hypersensitivity. * subjects diagnosed with g6pdh deficiency. * taking other medicines that prolong qt: domperidone, ondansetron, cilostazol, antiarrhythmics (procainamide, amiodarone, flecainide, sotalol), macrolides (azithromycin, clarithromycin, erythromycin), quinolones (ciprofloxacin,), moxofloxacin,) neuroleptics (haloperidol, chlorpromazine, pimozide), antidepressants (citalopram, escitalopram), sulpiride, anticholinesterase drugs (donepezil) * denial to participate in the study

- staff members who do not provide direct care to residents. - residents with active sars-cov-2 infection present, or with symptoms compatible with covid19 confirmed by pcr test. - staff members with present or past sars-cov-2 infection, or with pcr-confirmed symptoms consistent with covid19. - history of qt interval prolongation or arrhythmias of any etiology. - presence of retinopathy of any etiology, changes in acuity or visual field. - severe hearing loss (requires the use of hearing aids). - structural heart disease. - history of non-structural heart failure, ischemic heart disease, scasest, or scacest - chronic liver disease. - alcoholism. - epilepsy. - for the participating professionals, pregnancy or suspected pregnancy (if they are planning pregnancy, or in fertilizer treatment, they must abandon the study). - subjects with known hdq hypersensitivity. - subjects diagnosed with g6pdh deficiency. - taking other medicines that prolong qt: domperidone, ondansetron, cilostazol, antiarrhythmics (procainamide, amiodarone, flecainide, sotalol), macrolides (azithromycin, clarithromycin, erythromycin), quinolones (ciprofloxacin,), moxofloxacin,) neuroleptics (haloperidol, chlorpromazine, pimozide), antidepressants (citalopram, escitalopram), sulpiride, anticholinesterase drugs (donepezil) - denial to participate in the study

- staff members who do not provide direct care to residents. - residents with active sars-cov-2 infection present, or with symptoms compatible with covid19 confirmed by pcr test. - staff members with present or past sars-cov-2 infection, or with pcr-confirmed symptoms consistent with covid19. - history of qt interval prolongation or arrhythmias of any etiology. - presence of retinopathy of any etiology, changes in acuity or visual field. - severe hearing loss (requires the use of hearing aids). - structural heart disease. - history of non-structural heart failure, ischemic heart disease, scasest, or scacest - chronic liver disease. - alcoholism. - epilepsy. - for the participating professionals, pregnancy or suspected pregnancy (if they are planning pregnancy, or in fertilizer treatment, they must abandon the study). - subjects with known hdq hypersensitivity. - subjects diagnosed with g6pdh deficiency. - taking other medicines that prolong qt: domperidone, ondansetron, cilostazol, antiarrhythmics (procainamide, amiodarone, flecainide, sotalol), macrolides (azithromycin, clarithromycin, erythromycin), quinolones (ciprofloxacin,), moxofloxacin,) neuroleptics (haloperidol, chlorpromazine, pimozide), antidepressants (citalopram, escitalopram), sulpiride, anticholinesterase drugs (donepezil) - denial to participate in the study